Developing a new therapy to replace secretory IgA for patients with Common Variable Immune Deficiency (CVID)
Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients
This study is testing a new nasal treatment using a special type of immune protein to help people with Common Variable Immune Deficiency (CVID) fight off infections better, especially in their lungs and nose, where they often get sick.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lactiga Us INC. NIH-funded |
| Lab location | 1 site (North Brunswick, United States) |
| Project ID | NIH-11067456 on NIH RePORTER |
What this research studies
This research focuses on creating a replacement therapy using human secretory IgA for patients suffering from Common Variable Immune Deficiency (CVID). The approach aims to address the limitations of current immunoglobulin replacement therapies, which primarily deliver IgG and do not effectively target the respiratory tract where infections are most common. By developing a therapy that can be administered to the nasal cavity, the research seeks to enhance the immune response in CVID patients, potentially reducing the frequency of infections. The study will involve preclinical testing to evaluate the safety and efficacy of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Common Variable Immune Deficiency, particularly those experiencing recurrent respiratory infections.
Not a fit: Patients who do not have Common Variable Immune Deficiency or those with other types of primary immunodeficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for CVID patients, potentially reducing their risk of severe infections.
How similar studies have performed: While there have been advancements in immunoglobulin therapies, this specific approach targeting secretory IgA for CVID is novel and has not been extensively tested in prior studies.
Where this research is happening
North Brunswick, United States
- Lactiga Us INC. — North Brunswick, United States (Active)
Researchers
- Principal investigator: Mane, Viraj Pramod — Lactiga Us INC.
- Study coordinator: Mane, Viraj Pramod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.